Infliximab: Efficacy in psoriasis.
Loading...
Date
2013-07
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Moderate to severe psoriasis often needs to be addressed with standard disease modifying therapies such as methotrexate, cyclosporine, acitretin or ultraviolet radiation, which have their potential benefits and limitations. The tumor necrosis factor-alpha (TNF-α) is elevated in psoriatic plaques compared to non lesional skin as well as in the plasma of patients with moderate to severe psoriasis. Infliximab, a TNF-α blocker, has been recommended for the treatment of moderate to severe plaque psoriasis in adults who have failed to respond to these therapies or who cannot tolerate them. Its specific action on the bound and membrane forms of the pro-inflammatory cytokine TNF-α has made it the molecule of choice for obtaining quicker and longer remission in recalcitrant cases. However, the widespread use of infliximab in the Indian subcontinent is limited by its cost. This article reviews the international guidelines for use of infliximab, its dosage patterns, and efficacy in chronic plaque psoriasis, nail psoriasis, erythrodermic psoriasis, and pustular psoriasis as well as Indian experience.
Description
Keywords
Infliximab, psoriasis, tumor necrosis factor–α
Citation
Arsiwala Shehnaz. Infliximab: Efficacy in psoriasis. Indian Journal of Dermatology, Venereology and Leprology. 2013 July; 79 Suppl(): S25-34.